Eugenia Negredo

Summary

Affiliation: Lluita contra la SIDA Foundation
Country: Spain

Publications

  1. pmc Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome
    Marta Curriu
    Institut de Recerca de la SIDA, IrsiCaixa HIVACAT, Institut d Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain
    J Transl Med 11:68. 2013
  2. pmc Time of progression to osteopenia/osteoporosis in chronically HIV-infected patients: screening DXA scan
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    PLoS ONE 7:e46031. 2012
  3. ncbi request reprint Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens
    Eugenia Negredo
    Germans Trias i Pujol University Hospital, Lluita contra la SIDA and IrsiCaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
    Antivir Ther 13:231-40. 2008
  4. ncbi request reprint Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins
    Eugenia Negredo
    Lluita contra la SIDA, Germans Trias i Pujol Hospital, Universitat Autonoma de Barcelona, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
    AIDS 20:2159-64. 2006
  5. ncbi request reprint Benefits and concerns of simplification strategies in HIV-infected patients
    Eugenia Negredo
    Lluita contra la SIDA Foundation, HIV Unit, Universitat Autonoma de Barcelona, Hospital Universitari Germans Trias i Pujol Barcelona, Spain
    J Antimicrob Chemother 58:235-42. 2006
  6. doi request reprint Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    AIDS Res Hum Retroviruses 25:451-5. 2009
  7. doi request reprint Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Barcelona, Spain
    Clin Infect Dis 49:892-900. 2009
  8. doi request reprint Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications
    Eugenia Negredo
    Lluita contra Sida Foundation, Institut de Recerca en Ciències de Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Infect Dis 50:1300-8. 2010
  9. doi request reprint Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients
    Jose Molto
    Lluita contra Sida Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 15:219-25. 2010
  10. ncbi request reprint The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy
    Eugenia Negredo
    Lluita contra la SIDA, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    AIDS 20:619-21. 2006

Detail Information

Publications69

  1. pmc Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome
    Marta Curriu
    Institut de Recerca de la SIDA, IrsiCaixa HIVACAT, Institut d Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain
    J Transl Med 11:68. 2013
    ..Although several immunological abnormalities have been described in CFS, their heterogeneity has limited diagnostic applicability...
  2. pmc Time of progression to osteopenia/osteoporosis in chronically HIV-infected patients: screening DXA scan
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    PLoS ONE 7:e46031. 2012
    ..Our objective was to assess how often a dual-energy x-ray absorptiometry (DXA) scan should be performed by assessing time of progression to osteopenia/osteoporosis...
  3. ncbi request reprint Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens
    Eugenia Negredo
    Germans Trias i Pujol University Hospital, Lluita contra la SIDA and IrsiCaixa Foundations, University of Barcelona, 08916 Badalona, Barcelona, Spain
    Antivir Ther 13:231-40. 2008
    ..We assessed whether a simple reduction of the ddl dose in patients receiving ddl (400 mg/day) and TDF could revert this side effect...
  4. ncbi request reprint Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins
    Eugenia Negredo
    Lluita contra la SIDA, Germans Trias i Pujol Hospital, Universitat Autonoma de Barcelona, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
    AIDS 20:2159-64. 2006
    ..To assess the efficacy, safety, and pharmacokinetic interactions of ezetimibe in HIV-infected patients with poorly controlled antiretroviral-associated dyslipidaemia while taking pravastatin alone...
  5. ncbi request reprint Benefits and concerns of simplification strategies in HIV-infected patients
    Eugenia Negredo
    Lluita contra la SIDA Foundation, HIV Unit, Universitat Autonoma de Barcelona, Hospital Universitari Germans Trias i Pujol Barcelona, Spain
    J Antimicrob Chemother 58:235-42. 2006
    ..An accurate analysis of each patient's history will be necessary in each case to determine whether a simplification strategy is appropriate...
  6. doi request reprint Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    AIDS Res Hum Retroviruses 25:451-5. 2009
    ..However, prolonged follow-up of these patients is recommended to detect unexpected long-term adverse reactions...
  7. doi request reprint Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Barcelona, Spain
    Clin Infect Dis 49:892-900. 2009
    ..This study aimed to evaluate in vivo the effects of NRTI withdrawal on mitochondrial parameters and body fat distribution...
  8. doi request reprint Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications
    Eugenia Negredo
    Lluita contra Sida Foundation, Institut de Recerca en Ciències de Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Infect Dis 50:1300-8. 2010
    ..Although antiretroviral therapy improves immune response, some human immunodeficiency virus-infected patients present unsatisfactory CD4 T cell recovery despite achieving viral suppression, resulting in increased morbidity and mortality...
  9. doi request reprint Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients
    Jose Molto
    Lluita contra Sida Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 15:219-25. 2010
    ..We explored a treatment simplification strategy to darunavir/ritonavir 900/100 mg once daily guided by the darunavir virtual inhibitory quotient (vIQ) in patients receiving salvage therapy with darunavir/ritonavir 600/100 mg twice daily...
  10. ncbi request reprint The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy
    Eugenia Negredo
    Lluita contra la SIDA, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    AIDS 20:619-21. 2006
    ..Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4...
  11. doi request reprint High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study
    Anna Bonjoch
    Lluita contra la SIDA Foundation, University Hospital Germans Trias, Barcelona, Spain
    AIDS 24:2827-33. 2010
    ..Low bone mineral density (BMD) is an emerging metabolic condition in HIV-infected patients; however, data on progression of this disease are scarce...
  12. ncbi request reprint Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Germans Trias i Pujol Hospital, Badalona, Spain
    Antivir Ther 11:47-51. 2006
    ..To assess if enfuvirtide (ENF) increases antiviral activity of a highly active four-drug antiretroviral (ARV) regimen containing lopinavir/ritonavir, efavirenz, lamivudine and tenofovir in ARV-naive, HIV-infected patients...
  13. ncbi request reprint Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Spain
    Antivir Ther 9:335-42. 2004
    ..To assess the efficacy and safety of a once-daily antiretroviral regimen in HAART-experienced subjects with long-lasting viral suppression...
  14. ncbi request reprint Longitudinal study on mitochondrial effects of didanosine-tenofovir combination
    Sonia Lopez
    Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 22:33-9. 2006
    ..The particular relevance of either ddI, TDF, or any interaction between them in such a mitochondrial dysfunction remains to be established...
  15. doi request reprint Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    AIDS Res Hum Retroviruses 26:1191-6. 2010
    ....
  16. doi request reprint Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Ther Drug Monit 32:93-6. 2010
    ..Atazanavir Ctroughs were compared between Days 0 and 28. Atazanavir and nevirapine Ctroughs at Day 28 were compared with historical controls receiving either 400 mg atazanavir once daily or 200 mg nevirapine twice daily...
  17. doi request reprint Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
    Jose A Muñoz-Moreno
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain
    J Neurovirol 16:208-18. 2010
    ..Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning...
  18. ncbi request reprint Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study)
    Eugenia Negredo
    Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Germans Trias i Pujol Hospital, Badalona, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 38:47-52. 2005
    ..To compare the efficacy and safety of a nucleoside-sparing approach with a conventional highly active antiretroviral therapy (HAART) regimen in antiretroviral-experienced patients with prolonged viral suppression...
  19. ncbi request reprint Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence
    Carmina R Fumaz
    Lluita contra la SIDA Foundation, HIV Unit Germans Trias i Pujol Hospital, Autonomous University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 38:560-5. 2005
    ..Efavirenz has been associated with neuropsychiatric disorders, although little is known about its long-term toxicity...
  20. ncbi request reprint Mild improvement in mitochondrial function after a 3-year antiretroviral treatment interruption despite persistent impairment of mitochondrial DNA content
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Curr HIV Res 8:379-85. 2010
    ..The ability of a prolonged antiretroviral treatment interruption to reverse mitochondrial toxicity was evaluated in a sub-study of TIBET, a prospective trial examining antiretroviral treatment interruption guided by CD4+ cell count...
  21. ncbi request reprint Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain
    Clin Infect Dis 41:901-5. 2005
    ..Individuals receiving both agents showed little additional increase in CD4+ cell count after week 8 of therapy, whereas those receiving 1 or neither of the agents had continuous increases over a 48-week period...
  22. ncbi request reprint Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, and Universidad Autonoma de Barcelona, Spain
    J Antimicrob Chemother 60:436-9. 2007
    ..The objective of this study was to assess the effectiveness and safety of monotherapy with lopinavir/ritonavir as a treatment simplification strategy in HIV-infected patients with viral suppression outside a clinical trial setting...
  23. ncbi request reprint Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects
    Jose Molto
    HIV Clinical Unit Lluita Contra Ia Sida Foundation, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 20:1283-8. 2004
    ..Previous STIs do not influence time off therapy when HAART is definitively discontinued in chronically HIV-infected subjects. CD4 nadir is an important factor in the treatment discontinuation decision...
  24. ncbi request reprint Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Clin Pharmacokinet 47:681-92. 2008
    ..It is coformulated with low doses of ritonavir in order to enhance its pharmacokinetic profile. After oral administration, plasma concentrations of lopinavir can vary widely between different HIV-infected patients...
  25. ncbi request reprint Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Ther Drug Monit 29:648-51. 2007
    ..Therapeutic drug monitoring may be useful in this setting...
  26. ncbi request reprint Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study
    Lidia Ruiz
    Retrovirology Laboratory, IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Infect Dis 188:977-85. 2003
    ..66; 95% confidence interval, 0.47-0.93; P=.021). A prior STI seems to confer no additional benefit to subsequent virological or immunological outcomes of a salvage regimen...
  27. ncbi request reprint Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens
    Carmina R Fumaz
    HIV Unit, Fundació Lluita SIDA and IrsiCaixa Retrovirology Laboratory, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 29:244-53. 2002
    ....
  28. ncbi request reprint Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study
    Eugenia Negredo
    Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    Antivir Ther 9:889-93. 2004
    ..Alternation of antiretroviral drug regimens has been proposed as a novel treatment strategy for HIV infection. However, some concerns persist regarding antiviral efficacy, adherence, toxicity and resistance evolution in the long term...
  29. doi request reprint Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain
    J Antimicrob Chemother 68:2358-62. 2013
    ..Immune hyperactivation in immunodiscordant patients can induce residual HIV replication and limit CD4 T cell recovery. We assessed the impact of raltegravir intensification on CD4 T cell recovery and viral persistence...
  30. ncbi request reprint Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Barcelona, Spain
    J Antimicrob Chemother 61:400-4. 2008
    ..Cellular cholesterol is essential for HIV replication and may control HIV spread. HIV, in turn, appears to control cholesterol metabolism...
  31. doi request reprint Low levels of adherence to antiretroviral therapy in HIV-1-infected women with menstrual disorders
    Carmina R Fumaz
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain
    AIDS Patient Care STDS 23:463-8. 2009
    ..The subjective attribution of these irregularities to antiretrovirals seems to affect medication intake, possibly favoring negative clinical consequences...
  32. doi request reprint Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia
    Gloria Garrabou
    Mitochondrial Research Laboratory, Internal Medicine Department, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona and CIBER de Enfermedades Raras, CIBERER, Barcelona, Spain
    J Acquir Immune Defic Syndr 52:443-51. 2009
    ....
  33. doi request reprint Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial
    Anna Bonjoch
    HIV Unit and Fundació Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Barcelona, Catalonia, Spain
    J Antimicrob Chemother 68:1382-7. 2013
    ..To evaluate the safety and efficacy of switching the third drug of antiretroviral treatment to maraviroc in aviraemic subjects infected with R5 HIV...
  34. ncbi request reprint Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients
    Echeverria Patricia
    Germans Trias i Pujol University Hospital, Barcelona, Spain
    Curr HIV Res 8:467-70. 2010
    ..The high antiviral potency and low toxicity of saquinavir/ritonavir (SQV/r) prompted us to assess a viable strategy in chronic virologically suppressed HIV-infected patients...
  35. doi request reprint A brief and feasible paper-based method to screen for neurocognitive impairment in HIV-infected patients: the NEU screen
    Jose A Muñoz-Moreno
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain Universitat Autònoma de Barcelona, Bellaterra, Spain Universitat Politècnica de Catalunya, Barcelona, Spain Consorci Sanitari Hospital de Terrassa, Terrassa, Spain Universitat de Barcelona, Grup de Recerca Consolidat en Neuropsicologia, Barcelona, Spain and Institut per la Recerca de la SIDA, Fundacio irsiCaixa, Badalona, Spain
    J Acquir Immune Defic Syndr 63:585-92. 2013
    ..Practical screening methods are necessary to detect neurocognitive impairment (NCI) in HIV-infected patients. We aimed to find a brief and feasible paper-based tool to facilitate the diagnosis of an HIV-associated neurocognitive disorder...
  36. ncbi request reprint Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances
    Eugenia Negredo
    HIV Unit, Fundació de la Lluita contra la SIDA, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    AIDS Patient Care STDS 20:829-37. 2006
    ..Similar results were observed for all degrees of severity and between genders. Polyacrylamide gel provided the longest lasting benefits...
  37. pmc Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile
    Jose R Santos
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    PLoS ONE 7:e37442. 2012
    ....
  38. doi request reprint Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults
    Elena Ferrer
    HIV Unit, Service of Infectious Diseases, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:1061-5. 2011
    ..008) and subcutaneous fat (42%, p = 0.008). These data suggest that switching from LPV/r to ATV/r is associated with increased trunk fat, both subcutaneous and visceral...
  39. doi request reprint Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir
    Maria Saumoy
    Infectious Disease Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
    Antivir Ther 16:459-68. 2011
    ....
  40. ncbi request reprint Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review
    Jose A Muñoz-Moreno
    Lluita Contra la SIDA Foundation Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain
    AIDS Rev 11:103-9. 2009
    ..Different recommendations on the assessment of efavirenz-related adverse events are also provided...
  41. pmc Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Clinic, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    Antimicrob Agents Chemother 55:326-30. 2011
    ..Although no dose adjustment is required, monitoring darunavir concentrations on an individual basis may give reassurance in this setting...
  42. ncbi request reprint Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide
    Anna Bonjoch
    Lluita contra la SIDA Foundation, AIDS Care Unit, Hospital Universitari Germans Trias i Pujol, Universitat Auntònoma de Barcelona, Badalona, Spain
    AIDS 20:1896-8. 2006
    ..5%) and in no patients, respectively, (P = 0.007). The CD4 cell decrease in failure patients was 5% (P = ns). These results suggest that enfuvirtide should be maintained until new active drugs became available...
  43. doi request reprint Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Antimicrob Chemother 62:784-92. 2008
    ....
  44. doi request reprint Saquinavir exposure in HIV-infected patients with chronic viral hepatitis
    Jose Molto
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Antimicrob Chemother 63:992-7. 2009
    ....
  45. ncbi request reprint Reversal of HIV-1-associated osteoporosis with once-weekly alendronate
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain
    AIDS 19:343-5. 2005
    ..Improvements in trochanter BMD were obtained after 2 years. Once-weekly oral alendronate may be an effective and safe treatment for HIV-1-associated osteoporosis...
  46. ncbi request reprint Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts
    Bonaventura Clotet
    Retrovirology Laboratory irsiCaixa Foundation, Barcelona, Spain
    HIV Clin Trials 3:316-23. 2002
    ..Although L90M has been observed rarely to date under nelfinavir selection, data on the relative incidence of these two mutations on failure of first-line nelfinavir HAART are sparse...
  47. doi request reprint Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery
    Marta Massanella
    AIDS Research Institute, IrsiCaixa HIVACAT, Institut d Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Catalonia, Spain
    AIDS 26:2285-93. 2012
    ..Immunodiscordance is characterized by partial CD4 T-cell immunodeficiency and increased inflammation, activation and immunosenescence in both CD4 and CD8 T cells...
  48. ncbi request reprint Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial
    Javier Martinez-Picado
    IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Carretera de Canyet s n, 08916 Badalona, Spain
    Ann Intern Med 139:81-9. 2003
    ..Mathematical modeling has suggested that alternating antiretroviral regimens while patients' viral load remains suppressed would minimize HIV resistance mutations...
  49. doi request reprint Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients
    Jose A Muñoz-Moreno
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 24:1301-7. 2008
    ..We found differences in neurocognitive functioning in relation to nadir CD4 count in HIV-infected patients. Attention should be given to this value in the management of neurocognitive protection in HIV infection...
  50. ncbi request reprint Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis
    Jose Molto
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Clin Pharmacokinet 46:85-92. 2007
    ..To assess the influence of hepatitis C virus (HCV) co-infection and the extent of liver fibrosis on lopinavir/ritonavir pharmacokinetics in HIV-infected patients without liver function impairment...
  51. ncbi request reprint Evaluation of the anti-HIV activity of statins
    Gemma Moncunill
    Retrovirology Laboratory IrsiCaixa and HIV Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Spain
    AIDS 19:1697-700. 2005
    ..No anti-HIV activity was detected at subtoxic concentrations and simvastatin did not induce a significant change in the mean viral load or CD4 cell count in study patients. We caution on the use of statins as antiretroviral agents...
  52. doi request reprint Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen. Etraswitch Study
    Patricia Echeverria
    Department of HIV, Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Autonomous University of Barcelona, Barcelona, Spain
    PLoS ONE 9:e84676. 2014
    ..It has also shown antiviral efficacy in antiretroviral-naïve patients. However, data on the switching from protease inhibitors (PI) to ETR are lacking...
  53. ncbi request reprint Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Belvitge, L Hospitalet de Llobregat, Barcelona, Spain
    Curr HIV Res 10:673-8. 2012
    ..To describe the efficacy and tolerability of switching to raltegravir (RAL) in virologically suppressed HIV-1-infected patients during routine clinical practice...
  54. doi request reprint High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy
    Anna Bonjoch
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Autonomous University, Barcelona, Spain
    Antiviral Res 96:65-9. 2012
    ....
  55. pmc Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Clinic, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antimicrob Agents Chemother 56:2837-41. 2012
    ..19) for the concentration at the end of the dosing interval. In summary, coadministration of silymarin with darunavir-ritonavir seems to be safe in HIV-infected patients; no dose adjustment for darunavir-ritonavir seems to be necessary...
  56. doi request reprint Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort
    Anna Bonjoch
    University Hospital Germans Trias, Barcelona, Spain
    Antiviral Res 88:347-54. 2010
    ....
  57. ncbi request reprint Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study
    Jose A Muñoz-Moreno
    Lluita contra la SIDA Foundation, Badalona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 23:1166-75. 2007
    ....
  58. ncbi request reprint HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain
    Beatriz Mothe
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Catalonia, Spain
    Curr HIV Res 7:597-600. 2009
    ..Based on our findings, we suggest some recommendations regarding the management of this growing population...
  59. doi request reprint Pulse wave velocity as index of arterial stiffness in HIV-infected patients compared with a healthy population
    Patricia Echeverria
    Lluita contra la SIDA Foundation, Department of Internal Medicine, Germans Trias i Pujol University Hospital, Autonomous University of Barcelona, Barcelona, Spain and Department of Econometrics, Statistics and Spanish Economy, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 65:50-6. 2014
    ..Chronic HIV infection leads to premature atherosclerosis. Arterial stiffness is considered a subclinical marker of cardiovascular disease...
  60. pmc Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients
    Jose Molto
    Lluita contra la SIDA Foundation, HIV Clinic, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antimicrob Agents Chemother 56:5328-31. 2012
    ..In conclusion, the coadministration of E. purpurea with etravirine was safe and well tolerated in HIV-infected patients; our data suggest that no dose adjustment for etravirine is necessary...
  61. ncbi request reprint Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Badalona, Spain
    AIDS 16:1383-9. 2002
    ..Treatment simplification approaches in which PI are replaced by nevirapine (NVP) have been shown to improve PI-related toxicity...
  62. doi request reprint CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART
    Marta Massanella
    Fundació irsiCaixa HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Germans Trias, Universitat Autonoma de Barcelona, Spain
    AIDS 24:959-68. 2010
    ..However, the relative contribution of these factors is still unclear, strongly limiting the definition of appropriate therapeutic strategies for these patients...
  63. ncbi request reprint The changing face of HIV/AIDS in treated patients
    Josep M Llibre
    Lluita contra la SIDA Foundation, University Hospital Germans Trias, Barcelona 08916, Spain
    Curr HIV Res 7:365-77. 2009
    ..The present review focuses on these twelve areas of increasing interest for physicians currently facing successfully treated HIV+ patients...
  64. doi request reprint Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
    Daniel Podzamczer
    Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    J Acquir Immune Defic Syndr 50:390-6. 2009
    ..The strategy of switching nevirapine (NVP) twice daily to once daily was evaluated...
  65. ncbi request reprint HIV protease inhibitors and dyslipidemia
    Bonaventura Clotet
    HIV Unit and Retrovirology Laboratory, IrsiCaixa Foundation, Hospital Universitari, Germans Trias i Pujol, Carretera del Canyet s n Badalona, Barcelona, Spain
    AIDS Rev 5:19-24. 2003
    ..The need for lipid reduction therapy may be minimized with the use of new PIs that are comparable in efficacy to current PIs but do not negatively affect lipid levels...
  66. ncbi request reprint Impact of nevirapine on lipid metabolism
    Bonaventura Clotet
    Germans Trias i Pujol University Hospital, Barcelona, Spain
    J Acquir Immune Defic Syndr 34:S79-84. 2003
    ..These favorable lipid profiles may be of clinical benefit in reducing the risk for coronary artery disease in HIV-1 infected patients who are receiving long-term antiretroviral therapy...
  67. ncbi request reprint [Contribution of human papillomavirus second-generation hybrid capture test for the diagnosis of cervical pathology in HIV-infected outpatients]
    Guillem Sirera
    Unidad VIH, Servicio de Medicina, Hospital Universitario Germans Trias i Pujol, Universitat Autonoma de Barcelona, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
    Med Clin (Barc) 125:127-31. 2005
    ....
  68. ncbi request reprint Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression
    Eugenia Negredo
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    Clin Infect Dis 34:504-10. 2002
    ..Quality of life significantly improved for groups A and B. In patients receiving effective PI-based therapy, the replacement of the PI with either nevirapine or efavirenz is safe and virologically effective...
  69. ncbi request reprint [A 50-year-old male with AIDS and retroperitoneal mass]
    Eugenia Negredo
    Fundació de la Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espana
    Med Clin (Barc) 129:70-6. 2007